“港澳药械通”再落地：暨大附一院完成钇 90 玻璃微球手术

Core Insights - The successful implementation of the Y90 glass microsphere system at Jinan University First Affiliated Hospital marks a significant advancement in the treatment of primary liver cancer in the Guangdong-Hong Kong-Macao Greater Bay Area [1][2] Group 1: Medical Innovation - The Y90 glass microsphere is the first radioactive tumor treatment device approved in the Greater Bay Area and the first globally to receive FDA approval for primary liver cancer treatment [2] - This treatment combines the targeted killing of traditional internal radiation therapy with the minimally invasive safety of interventional techniques, allowing for personalized dosage tailored to individual patient needs [2][3] Group 2: Clinical Application - The Y90 microsphere therapy aims to reduce tumor size, control cancer embolism, and lower recurrence rates, potentially allowing patients to achieve surgical resection or liver transplantation for a cure [1][2] - The procedure is characterized by minimal invasiveness, utilizing DSA interventional equipment to inject millions of Y90 microspheres directly into the tumor's blood supply, minimizing damage to surrounding healthy tissue [3] Group 3: Policy and Market Impact - The Hong Kong-Macao Medical Device Policy facilitates the introduction of innovative medical products into the Greater Bay Area, enhancing patient access to advanced treatments and reducing healthcare costs [5][6] - This policy encourages innovation in medical products and service models, providing new market opportunities for pharmaceutical companies and promoting the development of the medical industry in the Greater Bay Area [5][6]